title: Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?
abstract: OBJECTIVE
  Currently bone marrow transplantation (BMT) with an HLA-identical sibling donor is recommended as optimal therapy for children with acquired severe aplastic anemia (SAA). Immunosuppressive therapy (IST) has become a very successful initial therapy for SAA in children lacking a related bone marrow donor. We wished to evaluate whether current IST regimens may be as efficacious as BMT.
  
  
  METHODS
  A retrospective review identified children treated for SAA over a 12-year period. Children with a related donor received a BMT. Children lacking a donor were treated with IST followed by a "rescue" BMT if IST was ineffective. IST consisted of anti-thymocyte globulin and steroid +/- cyclosporine A. Transfusion independence and survival rates were compared between the two groups.
  
  
  RESULTS
  Twenty-seven children were identified. Nine received a related BMT; seven of these survive and are transfusion independent (median follow-up 54 months). Sixteen of 18 patients who received IST are transfusion-independent survivors, including three of four patients who received a rescue BMT (median follow-up 33.5 months). Actuarial survival is 75% (95% CI = 45%, 105%) and 92% (95% CI = 78%, 107%) for the BMT and IST groups, respectively (p = 0.15). Severe toxicity was not experienced by any patient as a result of IST.
  
  
  CONCLUSIONS
  Equivalent rates of transfusion independence and survival were experienced by patients receiving BMT and IST. We propose that a prospective trial be undertaken to evaluate IST as initial therapy in all children with SAA, to be followed by BMT if there is inadequate response.
authors.affiliation: Division of Pediatric Hematology-Oncology and Bone Marrow Transplantation, University of British Columbia, Vancouver, Canada.
authors.forename: E R
authors.initials: ER
authors.lastname: Lawlor
authors.forename: R A
authors.initials: RA
authors.lastname: Anderson
authors.forename: J H
authors.initials: JH
authors.lastname: Davis
authors.forename: C J
authors.initials: CJ
authors.lastname: Fryer
authors.forename: S L
authors.initials: SL
authors.lastname: Pritchard
authors.forename: P C
authors.initials: PC
authors.lastname: Rogers
authors.forename: J K
authors.initials: JK
authors.lastname: Wu
authors.forename: K R
authors.initials: KR
authors.lastname: Schultz
mesh_terms: D000293:Adolescent; D000741:Anemia, Aplastic / Q000628:therapy*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D001955:British Columbia; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents